Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Total voting rights
December 02, 2013 02:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
Oxford, UK, 2 December 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 482,766,686 Ordinary shares of 1 pence each, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 482,766,686.
The above figure of 482,766,686 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Cairn Financial Advisers (Nominated Adviser) Tony Rawlinson / Liam Murray | Tel: +44 (0)20 7148 7900 |
| Hybridan LLP (Broker) Claire Louise Noyce / William Lynne | Tel: +44 (0)207 947 4350 / 4361 |